Drug Trial Radar · NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
620
Planned (sponsor's estimate)
Start
Aug 12, 2024
Primary completion
Jun 12, 2028
Study completion May 16, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Conditions
- Biliary Tract Cancer
Interventions
GemcitabineDrug
Standard of care chemotherapy by intravenous infusion
CisplatinDrug
Standard of care chemotherapy by intravenous infusion
DurvalumabDrug
Standard of care immunotherapy by intravenous infusion
Trastuzumab deruxtecanDrug
Experimental therapy by intravenous infusion
RilvegostomigDrug
Experimental therapy by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomigTime frame: Until all patients have completed at least 1 full Cycle (each cycle is 21 days)
- Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) populationTime frame: From date of treatment randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)
Locations
272 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Scottsdale, Arizona · Recruiting
Research Site
Tucson, Arizona · Withdrawn
Research Site
Tucson, Arizona · Recruiting
Research Site
Fullerton, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Alamitos, California · Suspended
Research Site
Los Angeles, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Walnut Creek, California · Withdrawn
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Washington D.C., District of Columbia · Not yet recruiting
Research Site
Fort Myers, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
St. Petersburg, Florida · Recruiting
Research Site
Tampa, Florida · Suspended
Research Site
West Palm Beach, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Coeur d'Alene, Idaho · Withdrawn
Research Site
Chicago, Illinois · Recruiting
Research Site
Niles, Illinois · Recruiting
Research Site
Towson, Maryland · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Worcester, Massachusetts · Withdrawn
Research Site
Detroit, Michigan · Withdrawn
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
Kansas City, Missouri · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Albuquerque, New Mexico · Withdrawn
Research Site
New York, New York · Withdrawn
Research Site
White Plains, New York · Recruiting
Research Site
Cleveland, Ohio · Suspended
Research Site
Cleveland, Ohio · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Pittsburgh, Pennsylvania · Not yet recruiting
Research Site
Greenville, South Carolina · Recruiting
Research Site
Nashville, Tennessee · Withdrawn
Showing 40 of 272 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.